Action INVO INVO BIOSCIENCE, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués INVO Bioscience, Inc.

Actions

INVO

US44984F4019

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:01 15/07/2024 		Varia. 5j. Varia. 1 janv.
0,8108 USD +2,86 % Graphique intraday de INVO Bioscience, Inc. +3,96 % -39,94 %
15/05 INVO Bioscience, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
16/04 INVO Bioscience, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
INVO Reports Record First Quarter 2024 Financial Results
AQ
Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK
AQ
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
INVO Bioscience : Reports Fourth Quarter and Full Year 2023 Financial Results - Form 8-K
PU
INVO Bioscience : Private Placement - Form 8-K
PU
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
AQ
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal
AQ
INVO Bioscience, Inc. - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK Bispecific Antibodies and Optimally Engineered Off-The-Shelf Natural Killer Cell Therapies
AQ
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
AQ
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
PR
INVO Reports Record Third Quarter 2023 Financial Results
PR
BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger
AQ
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
PR
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants
PR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, INVO, NM
PR
INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVO
BU
Shareholder Alert: Ademi LLP investigates whether INVO Bioscience, Inc. has obtained a Fair Price in its transaction with NAYA Biosciences
PR
INVO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of INVO Bioscience, Inc. Is Fair to Shareholders
BU
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action INVO
  4. Actualités INVO Bioscience, Inc.
  5. Communiqués